MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming
ASCO Annual Meeting 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced the publication of three abstracts which were accepted for the 2016
American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from
June 3 to June 7 in Chicago, Illinois, USA. The abstracts include updated
clinical data on the Company's proprietary drug candidate MOR202 from a phase
1/2a study in patients with multiple myeloma as well as a patient subgroup
analysis from the phase 2 study of MOR208 in non-Hodgkin's lymphoma (NHL). The
MOR202 abstract has also been selected by the conference organizers for
discussion in a separate session. In addition, partners of MorphoSys will
present data on several HuCAL antibodies that are currently in clinical
development.
"We are delighted to publish a new package of clinical data at the preeminent
conference on clinical oncology. The data set provides additional insight into
the progress of our lead cancer compounds MOR208 and MOR202," commented Dr.
Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For MOR202, we
are in particular looking forward to presenting additional efficacy data from
the dose escalation Phase 1/2a study in multiple myeloma in combination with
lenalidomide and with pomalidomide."
List of abstracts relating to MorphoSys's proprietary programs
Abstract #8012
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or
refractory multiple myeloma: Data from clinically relevant cohorts from a phase
1/2a study.
The poster presentation will include safety results and, in particular, efficacy
from additional patient cohorts receiving the anti CD38 antibody MOR202 alone
and in combination with pomalidomide or lenalidomide from the ongoing trial. The
poster presentation will take place on Monday, June 6, 8:00 am - 11:30 am CDT,
as part of the Hematologic Malignancies - Plasma Cell Dyscrasia track. The
findings will be discussed at the poster discussion session on Monday, June
6, 2016, 3:00 PM - 4:15 PM CDT, at E354b.
Abstract #7545
Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma
cohorts from a phase 2a study of single-agent MOR208 in patients with relapsed
or refractory non-Hodgkin's lymphoma (R-R NHL).
The poster presentation will include a subgroup analysis of an open-label,
multicenter, phase 2a study of the anti-CD19 antibody MOR208 in R-R NHL patients
progressing after at least one prior rituximab-containing therapy, as described
in the abstract. The poster presentation will take place on June 6, 8:00 am -
11:30 am CDT, as part of the Hematologic Malignancies - Lymphoma and Chronic
Lymphocytic Leukemia track.
Abstract #TPS7572
A phase 2 study of MOR208 plus idelalisib in patients with relapsed or
refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma
(SLL) previously treated with a Bruton's tyrosine kinase inhibitor
The poster presentation will include the trial design of an intended phase 2
study (COSMOS), which was originally planned to evaluate MOR208 in combination
with idelalisib in CLL and SLL, in particular ibrutinib-refractory CLL, as
described in the abstract. After the discontinuation of several combination
trials of idelalisib with other compounds and clinical holds by the regulatory
authorities in Europe and the U.S., this planned trial is currently under review
and discussions with regulatory authorities are ongoing. The poster presentation
will take place on June 6, 8:00 am - 11:30 am CDT, as part of the Hematologic
Malignancies - Lymphoma and Chronic Lymphocytic Leukemia track.
List of abstracts for programs from MorphoSys's partnered discovery business
Additionally, MorphoSys's partners will present data for several HuCAL
antibodies, which are currently in clinical development:
Abstract #TPS8576
A pivotal randomized phase 2 study of anetumab ravtansine or vinorelbine in
patients with advanced or metastatic pleural mesothelioma after progression on
platinum/pemetrexed-based chemotherapy (NCT02610140).
Abstract #8564
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in
combination with etoposide and platinum (EP) in patients (pts) with untreated
extensive-stage small-cell lung cancer (ED-SCLC).
Abstract #530
Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-
neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in
hormone receptor-positive (HR+) locally advanced or metastatic breast cancer
(BC): primary phase 1b results.
Abstract #3002
Phase 1b study of PF-05082566 in combination with pembrolizumab in patients with
advanced solid tumors.
Abstract #2516
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody)
with Paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-
negative breast cancer (BC).
Abstract #2509
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine
(AR).
The full abstracts can be accessed online at http://abstracts.asco.org/.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties, Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2013642/746305.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2013642]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Klondike Gold Announces $1,200,000 Private PlacementDatum: 19.05.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 472194
Anzahl Zeichen: 8714
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 332 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
